GLP-1 Medications Provide Liver Protection Independent of Weight Loss, New Study Finds
While the global conversation surrounding GLP-1 receptor agonists—such as Ozempic and Mounjaro—has focused largely on their ability to reduce weight, new research suggests these drugs offer significant health benefits that go beyond the scale. A collaborative study has revealed that semaglutide, the active component in these medications, directly improves liver function even in patients who do not experience significant weight loss.
The research, published in Cell Metabolism, was a joint effort between the LTRI at the University of Toronto and the CiMUS at the University of Santiago de Compostela (USC), with co-financing from European funds. The findings provide a critical breakthrough in understanding how these drugs combat metabolic liver disease, suggesting that the benefits are not merely a byproduct of shedding pounds.
According to the study, the GLP-1 receptor—the primary target for semaglutide—is located within a very specific group of endothelial cells in the liver. These cells serve as coordinators for overall hepatic function. When semaglutide activates these receptors, it triggers a signaling network that reduces inflammation, decreases fibrosis, and promotes the recovery of liver tissue.
The project was led by biologist María Jesús González Rellán and developed within the research group of Daniel Drucker, a recognized pioneer in the development of Ozempic and recipient of the 2024 Princess of Asturias Award for Scientific Research. This discovery shifts the medical understanding of how GLP-1-based therapies operate, moving the focus from systemic weight reduction to direct organ-specific action.
“Identifying these direct mechanisms helps us better understand their efficacy and opens the door to developing more specific therapies and identifying which patients can benefit most from these treatments,” stated González Rellán.
For years, clinicians had observed a puzzling phenomenon: some patients showed marked liver improvement despite minimal changes in weight. This research finally provides a biological explanation for those observations. By demonstrating that the medication acts directly on the liver’s cellular architecture, the study underscores a broader therapeutic potential for treating metabolic liver diseases regardless of a patient’s BMI.
This discovery is particularly significant for public health, as it suggests that the clinical utility of GLP-1 medications extends to a wider range of patients than previously thought, potentially guiding more personalized treatment strategies for liver health.
